On World Diabetes Day, we at Abarceo Pharma AB stand with the millions of people around the world living with type 1 diabetes – a chronic autoimmune disease with no apparent treatment. Abarceo pledges to bring a new, disease modifying, treatment to type -1 and type -2...
Abarceo attended the Nordic Life Science Days in Gothenburgh on October 13–14, 2025. Two days of instense partnering and finance discussions. Abarceo where happy to present the marvelous development of Abarceo Pharma in Mitochondrial repair and the Type 1 Diabetes...
On September 23, BioStock’s event Investing in Life Science 2025 took place in Stockholm. It was a day full of insights, inspiration, innovation and panel discussions. Abarceo’s CEO Adam Bruce attended the event and presented Abarceo’s development...
We are proud to present groundbreaking data at the 5th Swedish Diabetes Summit, revealing a novel approach to treating type 2 diabetes through VDAC1 oligomerization inhibitors. We share our exciting poster presented by our Principal Scientist Ruchi Jain and our...
World Diabetes Day on November 14 raised awareness of diabetes as one of the greatest public health challenges of our time, along with the importance of ensuring access to adequate care for everyone affected. Claes Wollheim, founder of Abarceo Pharma, has dedicated...
Recent Comments